Daniel J Weisdorf

Medicine & Life Sciences

1. Cell Transplantation 100%
2. Graft vs Host Disease 95%
3. Transplants 73%
4. Bone Marrow 64%
5. Unrelated Donors 59%
6. Bone Marrow Transplantation 58%
7. Transplantation 57%
8. Allogeneic Cells 54%
9. Tissue Donors 47%
10. Survival 38%
11. Acute Myeloid Leukemia 37%
12. Homologous Transplantation 33%
13. Fetal Blood 32%
14. Hematopoietic Stem Cell Transplantation 31%
15. Recurrence 31%
16. Leukemia 29%
17. Precursor Cell Lymphoblastic Leukemia-Lymphoma 28%
18. Mortality 24%
19. Confidence Intervals 23%
20. Siblings 22%
21. Myelodysplastic Syndromes 15%
22. Autologous Transplantation 15%
23. Natural Killer Cells 14%
24. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 14%
25. Stem Cell Transplantation 13%
26. Whole-Body Irradiation 13%
27. Cyclophosphamide 13%
28. Therapeutics 13%
29. Peripheral Blood Stem Cells 12%
30. Incidence 11%
31. Survivors 11%
32. Drug Therapy 10%
33. Mycophenolic Acid 9%
34. Multiple Myeloma 9%
35. KIR Receptors 9%
36. Clinical Trials 9%
37. Disease-Free Survival 9%
38. Infections 9%
39. Non-Hodgkin's Lymphoma 9%
40. Hematologic Neoplasms 8%
41. Transplant Recipients 8%
42. Allografts 8%
43. fludarabine 8%
44. Antilymphocyte Serum 7%
45. Cytomegalovirus 7%
46. HLA Antigens 7%
47. Cytogenetics 7%
48. Lymphoma 7%
49. Stem Cells 6%